Company:  SYNERGY PHARMACEUTICALS, ... (SGYPQ)
Form Type:  8-K
Filing Date:  3/14/2019 
CIK:  0001347613 
Address:  420 LEXINGTON AVENUE
SUITE 2012
 
City, State, Zip:  NEW YORK, New York 10170 
Telephone:  212-297-0020 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.01  
Change: 
-0.001 (-7.02%)  
Trade Time: 
02:57 PM EST  
Market Cap: 
$2.73M
Trade SGYPQ now with

© 2019  
Description of Business
Unless the context requires otherwise, the words "Synergy," "the Company," "we," "us," refer to Synergy Pharmaceuticals Inc. and, where appropriate, our subsidiaries. TRULANCE® is a trademark of Synergy Pharmaceuticals Inc. Any other trademarks reference in this Form 10-K are the property of their respective owners. All rights reserved. Business Overview Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. We have pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. We discovered and own 100% worldwide rights to our proprietary uroguanylin based GI platform which includes one commercial product and one development stage compound.
Register and access this filing in:     
  FORM 8-K
    SECTION 1 BUSINESS AND OPERATIONS
      Item 1.03 Bankruptcy or Receivership
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 99.1
  EXHIBIT 99.2